Evolocumab in STEMI
ST Elevation Myocardial Infarction
About this trial
This is an interventional treatment trial for ST Elevation Myocardial Infarction focused on measuring PCSK9, percutaneous coronary intervention, Infarct size
Eligibility Criteria
Inclusion Criteria: Typical ischemic chest pain persists for more than 30 minutes An elevation of an ST segment greater than 1 mm in two consecutive leads or new-onset left bundle branch block Presenting more than 12 hours after the onset of symptoms Exclusion Criteria: Previous history of myocardial infarction Previous history of coronary bypass surgery Cardiogenic shock that lasts more than 10 minutes or cardiac arrest Occlusion of the left main coronary artery Pregnant or have a plan of pregnancy Serum creatinine level is >2.5mg/dL or dialysis is required
Sites / Locations
- Sejong General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Evolocumab group
Control group
Evolocumab 420mg subcutaneous injection before primary PCI
without Evolocumab 420mg before primary PCI